AI-Assisted Blood Glucose Management Study
1 other identifier
interventional
131
1 country
1
Brief Summary
AI-driven health management tools can leverage continuous glucose monitoring (CGM), physical activity, and dietary data to provide real-time, individualized feedback, improving self-management and adherence. The X Life model integrates AI algorithms with wearable devices to dynamically adjust dietary and exercise recommendations. Preliminary user studies suggest good usability and user experience, with potential to promote positive behavior change. This trial aims to preliminarily evaluate whether the X Life AI system can improve glucose tolerance (measured by oral glucose tolerance test \[OGTT\] incremental area under the curve \[iAUC\]) in adults with prediabetes, providing effect size and protocol design reference for a future confirmatory randomized controlled trial. The investigators designed this trial with the assistance of a digital twin-based clinical research system (termed X Town).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Sep 2025
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
August 21, 2025
CompletedStudy Start
First participant enrolled
September 7, 2025
CompletedFirst Posted
Study publicly available on registry
September 8, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 23, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
November 30, 2025
CompletedFebruary 12, 2026
February 1, 2026
3 months
August 21, 2025
February 10, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
Change in OGTT Glucose Incremental Area Under the Curve (iAUC)
Difference between groups in the incremental area under the curve for plasma glucose concentration during a 2-hour oral glucose tolerance test (OGTT), calculated from measurements at 0, 60, and 120 minutes, adjusting for baseline values.
Baseline and at the end of the 28-day intervention period.
Secondary Outcomes (8)
Change in OGTT Plasma Glucose Levels
Baseline and at the end of the 28-day intervention period.
Change in Continuous Glucose Monitoring (CGM) Metrics
Baseline (7-day run-in period) and during the 28-day intervention period.
Change in OGTT Plasma Insulin Levels
Baseline and at the end of the 28-day intervention period.
Composite Body Composition Outcomes
Baseline and at the end of the 28-day intervention period.
Composite Metabolic Parameters
Baseline and at the end of the 28-day intervention period.
- +3 more secondary outcomes
Study Arms (2)
X Life Lifestyle Guidance
EXPERIMENTALStandard Care
ACTIVE COMPARATORInterventions
Participants will receive guideline-based lifestyle counseling according to national prediabetes prevention guidelines, delivered via mobile terminal, without AI-generated recommendations.
Participants will use the X Life system for 28 days, receiving real-time, personalized dietary and exercise recommendations triggered by glucose level and activity tracker data. Participants can interact with the system by uploading meal images, physical activity data, and wearable-derived metrics.
Eligibility Criteria
You may qualify if:
- Age 18-70 years
- Prediabetes (per ADA or WHO criteria)
- Stable lifestyle and body weight (±5%) for ≥3 months
- Owns and can operate a smartphone
- Able to understand and sign informed consent
You may not qualify if:
- Current glucose-lowering medication use
- Severe cardiovascular disease, liver/kidney dysfunction, or active malignancy
- Psychiatric or cognitive disorders affecting participation
- Planned major surgery or long-distance travel during the study
- Allergy/intolerance to CGM sensor materials
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Li Huatinglead
Study Sites (1)
Shanghai Sixth People's Hospital
Shanghai, China
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
August 21, 2025
First Posted
September 8, 2025
Study Start
September 7, 2025
Primary Completion
November 23, 2025
Study Completion
November 30, 2025
Last Updated
February 12, 2026
Record last verified: 2026-02